Keros Therapeutics (KROS) Treasury Shares (2019 - 2025)
Keros Therapeutics posted quarterly Treasury Shares of $21.1 million for Q4 2025, up 2827.36% on a QoQ basis from $721700.0 in Q3 2025.
Keros Therapeutics (KROS) has 1 years of Treasury Shares data on file, last reported at $384.6 million in Q4 2025.
- For the quarter ending Q4 2025, Treasury Shares changed N/A year-over-year to $21.1 million; the trailing twelve-month figure through Dec 2025 stood at $21.1 million (changed N/A YoY), and the FY2025 full-year result was $21.1 million, changed N/A from the prior year.
- Treasury Shares for Q4 2025 stood at $384.6 million.
- Across five years, Treasury Shares topped out at $21.1 million in Q4 2025 and bottomed at $721700.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 265,401.92 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 700,000.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 34.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | 21.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.13 Mn |
| Dec 31, 2025 | 384.56 Mn |
| Dec 31, 2025 | 21.13 Mn |
| Dec 31, 2025 | 384.56 Mn |
| Sep 30, 2025 | 721,700.00 |
| Sep 30, 2025 | 721,700.00 |
| Jun 30, 2025 | 867,775.00 |
| Jun 30, 2025 | 867,775.00 |
| Mar 31, 2025 | 882,775.00 |
| Mar 31, 2025 | 882,775.00 |
| Mar 31, 2020 | 17,278.00 |
| Mar 31, 2020 | 17,278.00 |
| Dec 31, 2019 | 34,557.00 |
| Dec 31, 2019 | 34,557.00 |